Kiniksa Pharmaceuticals (NASDAQ:KNSA) Upgraded to Buy at Wall Street Zen

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.

Several other equities analysts have also recently issued reports on KNSA. Wedbush reissued an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a "buy" rating and a $40.00 price objective on the stock. Finally, Jefferies Financial Group upped their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals presently has an average rating of "Buy" and an average target price of $38.80.

Kiniksa Pharmaceuticals Price Performance

Shares of NASDAQ:KNSA traded up $0.57 during trading on Friday, hitting $28.30. 907,293 shares of the company were exchanged, compared to its average volume of 515,189. The stock has a market capitalization of $2.07 billion, a P/E ratio of -202.13 and a beta of 0.06. Kiniksa Pharmaceuticals has a 12-month low of $17.38 and a 12-month high of $30.69. The firm's 50 day moving average price is $25.12 and its 200-day moving average price is $22.17.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. During the same quarter in the previous year, the firm earned ($0.25) EPS. The company's revenue was up 72.5% compared to the same quarter last year. As a group, equities research analysts anticipate that Kiniksa Pharmaceuticals will post -0.55 EPS for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, Director Barry D. Quart sold 12,336 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $30.39, for a total value of $374,891.04. Following the transaction, the director now directly owns 12,546 shares in the company, valued at approximately $381,272.94. This represents a 49.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Eben Tessari sold 45,042 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $30.51, for a total transaction of $1,374,231.42. Following the completion of the transaction, the chief operating officer now owns 72,363 shares in the company, valued at approximately $2,207,795.13. This trade represents a 38.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 443,906 shares of company stock worth $12,081,708. Corporate insiders own 53.48% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after acquiring an additional 568 shares during the period. US Bancorp DE purchased a new position in shares of Kiniksa Pharmaceuticals during the 1st quarter worth about $33,000. Asset Management One Co. Ltd. purchased a new position in shares of Kiniksa Pharmaceuticals during the 1st quarter worth about $41,000. Wealthquest Corp purchased a new position in shares of Kiniksa Pharmaceuticals during the 1st quarter worth about $42,000. Finally, Lazard Asset Management LLC purchased a new position in shares of Kiniksa Pharmaceuticals during the 4th quarter worth about $61,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.